Alan L. Rubino, Senior Industry Executive, Appointed Chairman of the Board of Directors of AMO Pharma
LONDON, August 19, 2021 / PRNewswire / – AMO Pharma Limited (“AMO Pharma”), a privately-held biopharmaceutical company focused on rare childhood neurogenetic disorders with limited or no treatment options, today announced that Alan L. Rubino has joined the board of directors of AMO Pharma directors as chairman effective August 16, 2021.
“Alan Rubino has extensive experience in all areas of drug development and commercialization, as well as in the planning and execution of numerous global license and acquisition agreements in the pharmaceutical and life sciences industries.” , said Ibraheem Mahmood, CEO of AMO Pharma. “He joins the Board of Directors of AMO Pharma at an important time for our company as we advance our pivotal REACH-CDM study evaluating the efficacy and safety of AMO-02 in the treatment of congenital myotonic dystrophy and continue to make significant progress with our other clinical stage assets in the pipeline. “
Mr. Rubino was most recently Managing Director and President of Emisphere Technologies, Inc. from 2012 to 2019. During his tenure at Emisphere, the company grew from $ 5 million to $ 800 market capitalization and was eventually acquired by Novo Nordisk for $ 1.8 billion. He was also co-founder and CEO of New American Therapeutics, Inc., which was eventually acquired by Renaissance Pharma, LLC., And held executive positions at Akrimax Pharmaceuticals, LLC and Pharmos Corporation. Most of his 24-year career has been with Hoffmann-La Roche, Inc. (now Genentech) as a member of the company’s executive committee, holding key leadership positions including marketing, sales, market research, project management, business operations, supply chain management and human resources. He obtained his bachelor’s degree in economics from Rutgers University and completed continuing education programs for senior executives at the University of Lausanne and Harvard Business School. He has been a member of the board of directors of Vericel Corporation since 2005 and a member of the board of directors of Bio NJ.
“I am very pleased to join the Board of Directors of AMO Pharma as the company continues to create new levels of momentum in its development programs and plans for several major clinical milestones,” said Mr. Rubino. “Backed by exceptional science, AMO has the potential to address critical unmet needs in the treatment of CWD1 and other difficult diseases. I look forward to applying my experience and industry connections to help the AMO team maximize opportunities with promising therapies that can have a profound impact on patient care for years to come. “
About AMO Pharma
AMO Pharma is a biopharmaceutical company working to identify and advance promising therapies for the treatment of severe and debilitating diseases in patient populations with high unmet needs, including rare and severe neurogenetic disorders of the childhood with limited or no treatment options. In addition to developing AMO-02 for congenital myotonic dystrophy, the company is also advancing AMO-01 as a clinical stage treatment for Phelan-McDermid syndrome and AMO-04 as a potential ready-to-use drug for Rett syndrome and related disorders. AMO-02, AMO-01, and AMO-04 are investigational drugs that have not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.
Public Relations Berry & Company
SOURCE AMO Pharma Limited